<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056172</url>
  </required_header>
  <id_info>
    <org_study_id>PNUYH-CHC001</org_study_id>
    <nct_id>NCT01056172</nct_id>
  </id_info>
  <brief_title>PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)</brief_title>
  <official_title>A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to evaluate the non-inferiority of sustained virologic response in
      peginterferon alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment
      duration of 24 weeks in patients who achieved rapid virologic response with genotype 2 CHC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent study (the ACCELERATE trial), treatment with peginterferon alfa-2a and ribavirin
      (800mg/day) for 16 weeks in patients infected with HCV genotype 2 or 3 result in a lower
      overall sustained virologic response rate than treatment with the standard 24 weeks regimen.
      Ribavirin was used as a flat dose (800mg/day) in ACCELERATE trial. But, previous studies
      which used the weight-based dose of ribavirin (800-1400mg/day) had shown that a treatment
      duration of 16 weeks was as effective as 24 weeks regimen in HCV genotype 2 patients with a
      RVR. But, there was too small number of patient enrolled study to argue logically about
      ACCELERATE trial. In this study, we aimed to confirm the non-inferiority peginterferon
      alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment duration of
      24 weeks in patients who achieved rapid virologic response with genotype 2 CHC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR)</measure>
    <time_frame>24 weeks post-treatment (week 40 or week 48)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>up to 24 weeks after last treatment visit</time_frame>
    <description>16 weeks treatment arm: 40 weeks
24 weeks treatment arm: 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory parameters</measure>
    <time_frame>up to 24 weeks after last treatment visit</time_frame>
    <description>16 weeks treatment arm: 40 weeks
24 weeks treatment arm: 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>up to 24 weeks after last treatment visit</time_frame>
    <description>16 weeks treatment arm: 40 weeks
24 weeks treatment arm: 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A. 24 weeks in RVR patients.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. 16 weeks in RVR patients.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a and Ribavirin</intervention_name>
    <description>PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (&lt;65kg: 800mg/day, 65-85kg: 1000mg/day, &gt;85kg: 1200mg/day)
Treatment duration: 16 weeks</description>
    <arm_group_label>B. 16 weeks in RVR patients.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a and Ribavirin</intervention_name>
    <description>PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (&lt;65kg: 800mg/day, 65-85kg: 1000mg/day, &gt;85kg: 1200mg/day)
Treatment duration: 24 weeks</description>
    <arm_group_label>A. 24 weeks in RVR patients.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age older than 18 years old

          2. Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test

          3. Detectable serum quantitative HCV-RNA

          4. HCV genotype 2 (VERSANT HCV Genotype Assay (LIPA))

          5. Patients have never been treated with traditional interferon plus ribavirin or
             peginterferon plus ribavirin

        Exclusion Criteria:

          1. Co-infection with hepatitis B and/or human immunodeficiency virus (HIV)

          2. History or other evidence of a medical condition associated with chronic liver disease
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,
             alcoholic liver disease, toxin exposures)

          3. Decompensated liver disease (Child-Pugh class B or C)

          4. Neoplastic disease within 5 years

          5. Evidence of drug abuse (including excessive alcohol consumption) within one year of
             study entry

          6. Women with ongoing pregnancy or breast feeding

          7. Hgb &lt; 11 g/dL in women or &lt; 12 g/dL in men at screening

          8. Neutrophil count &lt; 1500 cells/mm3 or platelet count &lt; 90,000 cells/mm3 at screening

          9. Serum creatinine level &gt; 1.5 times the upper limit of normal at screening

         10. Serum alpha-fetoprotein &gt; 100 ng/mL

         11. History of severe psychiatric disease, especially depression. Severe psychiatric
             disease is defined as treatment with an antidepressant medication or a major
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for
             at least 3 months at any previous time or any history of the following: a suicidal
             attempt, hospitalization for psychiatric disease, or a period of disability due to a
             psychiatric disease

         12. History of immunologically mediated disease, chronic pulmonary disease associated with
             functional limitation, severe cardiac disease, major organ transplantation or other
             evidence of severe illness, malignancy, or any other conditions which would make the
             patient, in the opinion of the investigator, unsuitable for the study

         13. History or other evidence of bleeding from esophageal varices or other conditions
             consistent with decompensated liver disease

         14. History of a severe seizure disorder or current anticonvulsant use

         15. Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)

         16. Inability or unwillingness to provide informed consent or abide by the requirements of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Tae Yoon, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki Tae Yoon, M.D</last_name>
    <phone>+82-55-360-2362</phone>
    <email>ktyoon@pusan.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongnam</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Tae Yoon, M.D</last_name>
      <phone>+82-55-360-2362</phone>
      <email>ktyoon@pusan.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ki Tae Yoon, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mong Cho</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Seok Kim</last_name>
      <phone>82-10-6360-2635</phone>
      <email>liverkys@schbc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Seok Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Heo, M.D, Ph.D</last_name>
      <phone>+82-51-240-7869</phone>
      <email>jheo@pusan.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Heo, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Young Woo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>633-165</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youn Jae Lee</last_name>
      <phone>08-10-7747-9281</phone>
      <email>yjyh0105@inje.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Uk Jung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youn Jae Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Ha Park, M.D.</last_name>
      <phone>+82-10-4718-4545</phone>
      <email>obgyy@medimail.co.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Ha Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Won Jang</last_name>
      <phone>82-11-204-9400</phone>
      <email>garden@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Woon Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung Hyun Kwon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Yong Park, M.D</last_name>
      <phone>+82-10-8353-0670</phone>
      <email>drpjy@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jun Yong Park, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Ki Tae Yoon</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Rapid virologic response</keyword>
  <keyword>Sustained virologic response</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

